July 2021 Simoa® Publications: Multiple Sclerosis, ALS and Down Syndrome
Hypermetabolism associated with worse prognosis of amyotrophic lateral sclerosis
He J, et al.
Journal of neurology. 2021
ALS
Humoral response to neurofilaments and dipeptide repeats in ALS progression
Puentes F, et al.
Annals of clinical and translational neurology. 2021
ALS
Comparative diagnosis interest of NfL and pNfH in CSF and plasma in a context of FTD-ALS spectrum
Escal J, et al.
Journal of neurology. 2021
ALS
The reliability and validity of DSM 5 diagnostic criteria for neurocognitive disorder and relationship with plasma neurofilament light in a down syndrome population
Pape SE, et al.
Sci Rep. 2021;11:13438
Down Syndrome
Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome
Lleó A, et al.
Nature communications. 2021;12:4304
Down Syndrome
Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study
Carmona-Iragui M, et al.
The Lancet Neurology
Down Syndrome
Circulating levels of tight junction proteins in multiple sclerosis: Association with inflammation and disease activity before and after disease modifying therapy
Olsson A, et al.
Multiple sclerosis and related disorders. 2021;54:103136
Multiple Sclerosis
The potential of serum neurofilament as biomarker for multiple sclerosis
Bittner S, et al.
Brain : a journal of neurology. 2021
Multiple Sclerosis
Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives
Jakimovski D, et al.
Neurodegenerative disease management. 2021
Multiple Sclerosis
Spinal Fluid Myeloid Microvesicles Predict Disease Course in Multiple Sclerosis
Gelibter S, et al.
Ann Neurol. 2021
Multiple Sclerosis
July 2021 Simoa® Publications in Other Therapeutic Areas
